ASND Ascendis Pharma A/S IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1612042 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY98.0%
TTM net income YoY39.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR141.4%
Net income 3-yr CAGR—
Margins
Gross margin86.8%
Operating margin-18.9%
Net margin-31.7%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-18.4%
ROIC (approx.)-111.1%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets112.5%
Debt / equity—
Current ratio1.04x
Interest coverage-1.69x
Cash quality & payout
Operating cash flow / net income-0.24x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 720.13M | 363.64M | 266.72M | 51.17M | 7.78M |
| Cost of revenue | 94.92M | 44.26M | 44.40M | 12.14M | 3.52M |
| Gross profit | 625.22M | 319.38M | 222.32M | 39.04M | 4.25M |
| R&D expense | 303.62M | 307.00M | 413.45M | 379.62M | 295.87M |
| SG&A expense | 457.87M | 291.14M | 264.41M | 221.23M | 160.18M |
| Operating income | -136.27M | -278.76M | -455.54M | -561.81M | -451.79M |
| Interest expense | 80.65M | 65.50M | 44.06M | 30.68M | 3.91M |
| Pretax income | -212.65M | -373.24M | -474.14M | -577.82M | -383.94M |
| Income tax | 15.38M | 4.84M | 7.30M | 5.38M | -367,000 |
| Net income | -228.03M | -378.08M | -481.45M | -583.19M | -383.58M |
| EPS (basic) | -3.76 | -6.53 | -8.55 | -10.40 | -7.00 |
| EPS (diluted) | -3.76 | -6.53 | -8.55 | -10.40 | -7.00 |
| Balance sheet | |||||
| Cash & equivalents | 616.04M | 559.54M | 392.16M | 444.77M | 446.27M |
| Receivables | 141.33M | 166.28M | 35.87M | 11.91M | 2.20M |
| Inventory | 301.53M | 295.61M | 208.93M | 130.67M | 75.41M |
| Current assets | 1.11B | 1.06B | 702.72M | 923.47M | 805.89M |
| PP&E, netmay include right-of-use assets (IFRS) | 146.48M | 98.71M | 110.63M | 129.09M | 126.05M |
| Total assets | 1.30B | 1.18B | 825.59M | 1.09B | 1.08B |
| Current liabilities | 1.07B | 907.86M | 736.51M | 171.27M | 100.36M |
| Short-term debt | 429.39M | 458.21M | 407.10M | 11.63M | 7.00M |
| Long-term debt | 385.25M | 365.08M | 223.00M | 387.56M | 97.97M |
| Total debt | 814.64M | 823.29M | 630.09M | 399.19M | 104.96M |
| Total liabilities | 1.47B | 1.29B | 971.28M | 826.39M | 201.29M |
| Shareholders' equity | -162.82M | -105.71M | -145.70M | 263.35M | 883.63M |
| Net debt | 198.60M | 263.74M | 237.93M | -45.58M | -341.31M |
| Cash flow statement | |||||
| Operating cash flow | 53.90M | -306.20M | -467.36M | -495.70M | -417.65M |
| Capital expenditure | — | — | 2.44M | 14.49M | 23.70M |
| Free cash flow | — | — | -469.80M | -510.19M | -441.35M |
| Investing cash flow | -8.48M | 6.88M | 286.47M | 61.73M | -110.58M |
| Financing cash flow | 36.33M | 443.93M | 134.29M | 396.77M | 351.39M |
| Stock-based compensation | 116.17M | 95.51M | 66.66M | 64.18M | 66.83M |
| Share buybacks | 17.40M | 0 | 0 | 105.31M | 21.61M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.